© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - Biocon to go Ahead with Syngene IPO, Listing Likely in July
Posted 19th May 2015

Biocon to go Ahead with Syngene IPO, Listing Likely in July

Biotechnology major Biocon on Wednesday filed a prospectus with market regulator Securities and Exchange Board of India (Sebi) for the Initial Public Offer (IPO) of its research arm, Syngene, through which it aims to raise around Rs 600 crore for funding research and development (R&D).

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Biocon to go Ahead with Syngene IPO, Listing Likely in July

Biocon to go Ahead with Syngene IPO, Listing Likely in July

View Biography
Amarchand & Mangaldas

Biopharmaceuticals major Biocon on Tuesday said that the unlocking of the value from its contract research subsidiary Syngene would help the company fund its research and development programmes.

Syngene has already filed the draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI), seeking approval for an initial public offering (IPO). The company is estimated to be raising around Rs 600 crore through this public issue.

“We are unlocking value from Syngene to fund our R&D programmes, which include a rich pipeline of biosimilars and novel biologics. This fund infusion will help accelerate these programmes which are at various stages of development currently,” said Kiran Mazumdar-Shaw, chairperson and managing director, Biocon.

This is an offer for sale (OFS) by Biocon of a part of its shareholding in Syngene. Biocon along with its subsidiary Biocon Research Limited (BRL), currently holds an 84.5 per cent equity stake in Syngene. The company is offering to sell up to 22 million equity shares of face value of Rs 10 each, through Syngene’s IPO.

The offer includes a reservation of two million equity shares for Biocon’s public equity shareholders, being individuals and Hindu Undivided Families (HUFs). The offer would constitute 11 per cent of the post offer paid-up equity share capital of the company.

Established in 1993, Syngene offers a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. The company’s service offerings also support the development of biosimilar and generic molecules.

During the nine months period-ended December 31, 2014, Syngene serviced 195 clients, ranging from multinational corporations to start-ups, including seven of the top 10 global pharmaceutical companies by sales for 2014.

Syngene had reported revenues of Rs 707.7 crore for the previous financial year-ended March 31, 2014 and Rs 617.5 crore for the nine months period ended December 31, 2014. Earlier this month, the company appointed Peter Bains as its Chief Executive Officer. Bains has been a part of Syngene since January 2010 as a director and has more than two decades of experience in the pharmaceutical space.

“Syngene has a proven track record of providing quality NME discovery, development and manufacturing services. It has long-standing partnerships with three of the world’s leading global healthcare organisations, including Bristol-Myers Squibb Co. and has attracted equity participation from India Value Fund recently, which is reflective of the scale, the value and the quality of the differentiated business model of Syngene,” added Mazumdar-Shaw.

Categories: Finance


You Might Also Like
Read Full PostRead - Eye Icon
How Warehouse Management Systems Reduce Business Expenditure
News
27/04/2022How Warehouse Management Systems Reduce Business Expenditure

Maximizing profits is one of the best ways to enhance the growth of your manufacturing firm. This enables you to get enough money to settle operating expenses and expand your investment.  

Read Full PostRead - Eye Icon
Key Legal Considerations When Drafting a Business Contract
Legal
01/05/2024Key Legal Considerations When Drafting a Business Contract

A well-written business contract is like an insurance policy, protecting you and your business in the event of something going wrong, and failing to have a written contract in place can be a costly mistake in the event of a contractual breach or a dispute.

Read Full PostRead - Eye Icon
The Crucial Role of Custom Store Signs in Small Business Success
News
03/07/2023The Crucial Role of Custom Store Signs in Small Business Success

In the cutthroat world of commerce, standing out and winning over clients can be a real struggle for small businesses. Custom store signs are a powerful instrument that can make a big difference. They’re often the initial touchpoint with potential custom

Read Full PostRead - Eye Icon
Tesla Stock Price Prediction: What Could Drive TSLA Stock Over the Next 5 Years?
Innovation
28/09/2026Tesla Stock Price Prediction: What Could Drive TSLA Stock Over the Next 5 Years?

Tesla’s future over the next five years will depend on much more than vehicle sales. The company operates across several markets, including electric vehicles, battery storage, charging infrastructure, software, and artificial intelligence. This combinati

Read Full PostRead - Eye Icon
In Debt for the First Time – How Your Business Needs to Treat the New Wave of Debtors
Finance
09/12/2022In Debt for the First Time – How Your Business Needs to Treat the New Wave of Debtors

As interest rates are hiked by ratios not seen in decades, the fallout from slowing economies across the world is likely to hit middle income earners as much, or more, as those on lower incomes. While those at the poorest ends of society are well-versed in bei

Read Full PostRead - Eye Icon
Abbott Completes the Acquisition of St. Jude Medical
Finance
10/01/2017Abbott Completes the Acquisition of St. Jude Medical

Abbott announced today it has completed the acquisition of St. Jude Medical, Inc., establishing the company as a leader in the medical device arena.

Read Full PostRead - Eye Icon
The Power of Now: Unleashing Success through Direct Response Marketing
News
06/08/2024The Power of Now: Unleashing Success through Direct Response Marketing

When instant gratification became the order of the day, direct response marketing emerged as one of the most heavy-duty strategies businesses can adopt. It entails immediate action on the consumers’ part and thus has the possibility of enhanced engagemen

Read Full PostRead - Eye Icon
Why Early Evidence Preservation Is a Business Risk Issue After Commercial Vehicle Crashes
Legal
27/01/2026Why Early Evidence Preservation Is a Business Risk Issue After Commercial Vehicle Crashes

The first calls after a commercial vehicle crash are usually practical. Someone alerts a supervisor. Dispatch tries to figure out whether the route can be covered. A customer asks where the load is. The safety manager starts building a timeline from the driver

Read Full PostRead - Eye Icon
The Role of Insurance in Protecting Long-Term Property Investments
Finance
13/11/2026The Role of Insurance in Protecting Long-Term Property Investments

Property gets called the patient asset. Buy it, leave it alone, watch it appreciate. That’s half right. Buildings do gain value over decades—but they do it sitting outdoors, exposed to weather, stuck in one spot they can’t leave. That immobility



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow